Accelerating the development and availability of paradigm-shifting medicines for patients in China and major Asian markets through strategic partnerships
Data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy were presented today at the @escardio 2023 Congress. The data were also published in @JAMACardio. #ESCCongress https://t.co/Q8fy9jPQJG
Today we announced our Q2 2023 financial results and shared recent corporate updates including key anticipated milestones. https://t.co/iEPq0VvwSV $LIAN
Today we recognize #WorldLungCancerDay. #LungCancer is the leading cause of cancer deaths worldwide, with China having one of the highest incidence rates. There is a great unmet need for new treatments for patients. Learn more from @WHO: https://t.co/zoysQqTEV4
Today is World #HeadandNeckCancer Awareness Day. At LianBio, we’re advancing new treatment options for cancer, including head and neck squamous cell carcinoma (HNSCC). Learn more about our ongoing clinical trial of NBTXR3 in locally advanced HNSCC:
https://t.co/HWI4X3sp8l
Congratulations to our partner, @TarsusRx , on the @US_FDA approval of XDEMVY™ for the treatment of #DemodexBlepharitis. Learn more: https://t.co/0h1w7UNMSZ
Next month, we will present efficacy and safety data of mavacamten, our cardiac myosin inhibitor for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, at the @escardio Congress 2023. #ESCCongress https://t.co/lPr2rsNKQf
Today we announced a clinical supply agreement with @AstraZeneca in China to evaluate BBP-398, an investigational SHP2 inhibitor, in combination with EGFR inhibitor osimertinib in a Phase 1 clinical study for non-small cell lung cancer with EGFR mutations.https://t.co/XRGRY9zcbb
We are pleased to announce that CAMZYOS® (mavacamten) was approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the Republic of Singapore. Learn more here: https://t.co/8tpVvnk1KT
Our mission is to bring transformative medicines to historically underserved patients in China and throughout Asia. Learn more about the various diseases we are targeting and explore the status of our ongoing clinical trials: https://t.co/pbn6gTw8yK
Our CEO Yizhe Wang will be participating in a fireside chat at the @GoldmanSachs Annual Global Healthcare Conference at 10 am PT/ 1 pm ET. Tune in here: https://t.co/RXdaeTNNYa
Tune into our fireside chat at the @Jefferies Global Healthcare Conference this afternoon at 4:30 for a discussion with management about recent company updates : https://t.co/RXdaeTOlNI
Today we announced the completion of enrollment in our pivotal Phase 3 LIBRA #ClinicalTrial of TP-03 in #Chinese patients with Demodex blepharitis. Read more: https://t.co/JTHicTpIuJ
Today we announced positive topline results from our Phase 2a proof-of-concept trial evaluating infigratinib in Chinese patients w/ locally advanced or metastatic #GastricCancer and receipt of Breakthrough Therapy Designation: https://t.co/Zk9kUOiHah
The LianBio management team is looking forward to participating in the @Jefferies Global Healthcare Conference and @GoldmanSachs Annual Global Healthcare Conference in June. Learn more here: https://t.co/On2aOFWi3y $LIAN
May is Cancer Research Month. In China, cancer is the leading cause of death with 4.5M diagnoses each year. LianBio has an #oncology pipeline dedicated to providing patients with proven therapeutics for #cancers. Learn about our recent strides: https://t.co/t5kC8xsCRJ #NCRM23
Today, our Chief Business Officer Brianne Jahn will be speaking on a panel at the 16th Global BioPharma Cross-border Summit 2023, hosted by @PwC, @MsqVentures & BioKatalyst Corporation. The panel will discuss the new opportunities that exist in China cross-border collaborations.
This week we announced our Q1 2023 financial result and shared recent corporate updates including key anticipated milestones. https://t.co/LOhpkUGPfM $LIAN
We are excited to announce that Mavacamten was approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the Macau Special Administrative Region. Learn more here: https://t.co/hwPbf0q7yG